Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abraxis BioScience Gets SFDA Nod For Metastatic Breast Cancer Drug In China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Abraxis BioScience received approval from China's State FDA to market its metastatic breast cancer drugAbraxane (paclitaxel albumin-bound particles for injectable suspension) in China, the company announced July 14

You may also be interested in...



Biocon Launches U.S. Breast Cancer Drug Abraxane in India

India's Biocon began marketing Abraxane (paclitaxel) in the country for treating breast cancer. Biocon licensed the drug last year from Abraxis BioSciences of the United States. The drug already is approved in 35 countries, but Biocon seeks to feed a growing need for the drug in India. The licensing agreement also covers more than 10 other countries in Asia where regulatory approval is sought, including Pakistan and Sri Lanka. (Click here for more

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel